Other Events ·
Monopar Therapeutics Inc. announced new analyses from its Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline)…
MNPRMonopar Therapeutics
Monopar Therapeutics Inc. announced new analyses from its Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) demonstrating greater neurologic and global clinical benefit compared to the standard of care in Wilson disease patients. The company will present these findings at the 12th Congress of the European Academy of Neurology (EAN) from June 27-30, 2026. Monopar Therapeutics Inc. is a biopharmaceutical company focused on developing therapeutic solutions for oncology and neurological diseases.